Panelists discuss the importance of real-world testing.
The potential for corneal staining warrants careful consideration and raises complex questions.
With lens-solution interactions becoming more common, we need to choose the right solution and convince our patients to stay with it.
Rather than staying with their same products, patients ofent shop around. The result can be problematic.
New diagnostic instruments and drug therapies are giving clinicians the tools they need to manage glaucoma better than ever before. Still, challenges remain. Read on for the latest news.
Understanding the barriers to compliance will help you develop new strategies that will lead to improved patient care.
New studies show travoprost lowers IOP and sustains lasting effects. These findings and others that show travoprost's efficacy and safety may encourage clinicians to use the drug in more patients to promote better outcomes.
With new trial results in hand, doctors will better understand how the different glaucoma agents fit into the therapeutic spectrum
The following case study will give clinicians new ideas on how to use travopost 0.004% (TRAVATAN solution) in their daily practicve to better manage glaucoma patients.